Pancreatic cancer — frontier options in Maryland

Prefer to look first? Browse the live map without signing up.

30 open options

TRIALPHASE1 / PHASE2RECRUITING
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
Cyclophosphamide · Fludarabine · Anti-KRAS G12V mTCR PBL — 1 site
TRIALPHASE3RECRUITING
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Atebimetinib · GnP · mGnP — 51 sites
TRIALPHASE2RECRUITING
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
HER3-DXd — 91 sites
TRIALPHASE2RECRUITING
Testing the Use of Chemotherapy After Surgery for High-Risk Pancreatic Neuroendocrine Tumors
Capecitabine · Temozolomide — 448 sites
TRIALPHASE2RECRUITING
A Phase II Nationwide, Fully Decentralized, Telemedicine Study of Pemigatinib in Adult Patients With Advanced or Metastatic Pancreatic Cancer With FGFR Genetic Alterations
Pemigatinib · Computed Tomography (CT) · Magnetic Resonance Imaging — 109 sites
TRIALPHASE1 / PHASE2RECRUITING
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
RMC-6236 — 21 sites
TRIALPHASE2RECRUITING
NC410 and FOLFIRINOX in Combination With Nivolumab With or Without Ipilimumab in Patients With Untreated Metastatic Pancreatic Cancer
Oxaliplatin · Irinotecan · Folinic Acid — 1 site
TRIALPHASE1 / PHASE2RECRUITING
A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors
ART0380 · Gemcitabine · Irinotecan — 82 sites
TRIALPHASE3RECRUITING
Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer
Biopsy Procedure · Biospecimen Collection · Capecitabine — 333 sites
TRIALNARECRUITING
The Vanguard Study: Testing a New Way to Screen for Cancer
Biospecimen Collection · Device Usage · Electronic Health Record Review — 44 sites
TRIALPHASE2RECRUITING
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
[18F]FAPI-74 · [18F]FDG — 1 site
TRIALPHASE1RECRUITING
SKL35501 With SKL35502 Imaging in Adults With NTSR1 Positive Advanced Solid Tumors
SKL35501 · SKL35502 — 5 sites
TRIALPHASE1RECRUITING
Mutant KRAS -Targeted Long Peptide Vaccine for Patients at High Risk of Developing Pancreatic Cancer
Cohort A: Patients at high risk of developing pancreatic cancer. · Cohort B: Patients must have evidence of a pancreatic cystic neoplasm — 1 site
TRIALPHASE1RECRUITING
A Study to Evaluate INCB161734 in Participants With Advanced or Metastatic Solid Tumors With KRAS G12D Mutation
INCB161734 · Cetuximab · Retifanlimab — 34 sites
TRIALPHASE1RECRUITING
Study of RMC-9805 in Participants With KRAS G12D-Mutant Solid Tumors
RMC-9805 · RMC-6236 — 17 sites
TRIALPHASE3RECRUITING
Intra-arterial Gemcitabine vs. IV Gemcitabine and Nab-Paclitaxel Following Radiotherapy for LAPC
Gemcitabine · nab-paclitaxel · RenovoCath — 42 sites
TRIALPHASE1 / PHASE2RECRUITING
A Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986523 Alone and in Combination With Anti-Cancer Agents in Participants With Advanced Solid Malignancies
BMS-986523 · Gemcitabine · Nab-Paclitaxel — 8 sites
TRIALPHASE3RECRUITING
The Cancer of the Pancreas Screening-5 CAPS5)Study
Secretin · MRI · Tumor marker gene test with CA19-9 — 9 sites
TRIALPHASE2RECRUITING
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)
BMS-986504 · Daraxonrasib · Nivolumab + Relatlimab FDC — 58 sites
TRIALPHASE1RECRUITING
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
PF-08046050 · bevacizumab · 5-Fluorouracil (5-FU) — 48 sites
TRIALPHASE3RECRUITING
Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
daraxonrasib · gemcitabine · nab-paclitaxel — 49 sites
TRIALPHASE1RECRUITING
A Study of LY4337713 in Participants With FAP-Positive Solid Tumors
LY4337713 — 30 sites
TRIALPHASE1RECRUITING
Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors
RMC-5127 · daraxonrasib · cetuximab — 9 sites
TRIALPHASE3RECRUITING
Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )
Zoldonrasib · Placebo · Oxaliplatin — 13 sites
TRIALPHASE3RECRUITING
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Setidegrasib · Oxaliplatin · Leucovorin — 79 sites
TRIALPHASE2 / PHASE3RECRUITING
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
ponsegromab · placebo — 223 sites
TRIALPHASE2RECRUITING
Natural History and Management of Von Hippel-Lindau (VHL) Associated Pancreatic Neuroendocrine Tumors
68-Gallium DOTATATE — 1 site
TRIALNARECRUITING
Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors
Total Pancreatectomy with Islet Autotransplantation (TPIAT) — 1 site
TRIALPHASE1 / PHASE2RECRUITING
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
VS-7375 · Cetuximab · Carboplatin + Pemetrexed + Pembrolizumab — 14 sites
TRIALPHASE3RECRUITING
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Biospecimen Collection · Distal Pancreatectomy · Lanreotide — 118 sites

Live from ClinicalTrials.gov, refreshed at most hourly · registry query ↗

Not medical advice. Trial0 is a navigation service, not a medical provider. Nothing here is medical advice or a recommendation to pursue any treatment; eligibility matching is informational, based on published registry criteria, and only the trial site or treating clinician can determine actual eligibility. Decisions belong with the patient and their own doctors.